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MxA iS a GTPase encoded by an interferon-inducible human gene. its constitutive xpression renders transfected mamma- 
lian cells resistant to infections with several different RNA viruses, including vesicular stomatitis virus (VSV). Differences 
in viral RNA levels of VSV-infected cells either expressing or lacking MxA indicated that VSV mRNA synthesis is the principal 
target of MxA action. We now used purified histidine-tagged MxA (His-My, A) that we produced in Escherichia coil to 
successfully inhibit VSV in vitro transcription, a reaction catalyzed by VSV ribonucleoprotein complexes isolated from virus- 
infected cells or from purified virions. MxA was inactive when added to preformed VSV mRNAs, arguing against he possibility 
that it has a negative effect on viral RNA stability. MxA inhibited both leader RNA and mRNA synthesis of VSV, suggesting 
that it interfered with transcription initiation. The degree of VSV inhibition correlated directly with the specific GTPase 
activities of the various wild-type MxA preparations. No inhibition of viral mRNA synthesis was observed when a C-terminally 
truncated, GTPase-inactive variant of His-MxA was added to the transcription reactions. Purified His-MxA-E645R, a mutant 
of MxA with normal GTPase activity whose range of antiviral activity in rive is altered so that it no longer inhibits VSV, 
showed no inhibitory effect on VSV in vitro transcription. Since MxA inhibited VSV RNA synthesis in the presence of GMP- 
PNP or GTP'yS, GTP analogs that are readily accepted by the viral polymerase but cannot be hydrolyzed by MxA, the 
possibility was excluded that MxA acts by depleting the viral polymerase for its nucleotide substrates. Thus, binding of 
GTP rather than its hydrolysis seems of importance for the anti-VSV activity of MxA. © 1995 Academic Press, Inc. 
INTRODUCTION 
MxA is a 76-kDa protein that accumulates to high lev- 
els in the cytoplasm of interferon (IFN)-treated human 
cells (Aebi et al., 1989; Horisberger et aL, 1990; Staeheli 
and Hailer, 1985). It exhibits potent GTPase activity 
(Horisberger, 1992; Pitossi eta/., 1993). When constitu- 
tively expressed in mouse 3T3 cells, it confers on these 
cells a high degree of resistance to influenza A virus 
and vesicular stomatitis virus (VSV) (Pavlovic et aL, 1990; 
Schnorretal., 1993; Staeheli and Pavlovic, 1991). It also 
protects transfected 3T3 cells from infection with Thogoto 
virus (Hailer eta/., 1993), a poorly characterized ortho- 
myxovirus. MxA further renders human U937 cells resis- 
tant to measles virus (Schnorr eta/., 1993). Mx proteins 
from mouse and rat exhibit antiviral activity in transfected 
cells (Meier eta/., 1990; Z(Jrcher et aL, 1992a), although 
their antiviral activities appear to be more selective. 
Other Mx proteins are devoid of recognized antiviral ac- 
tivity (Pavlovic and Staeheli, 1991). 
The mechanistic details of the Mx-mediated antiviral 
effects are presently unknown. It is unclear, for example, 
how the GTPase activity of Mx proteins may relate to 
their antiviral proPerties. Mutational analysis revealed 
that a functional GTP-binding consensus motif is neces- 
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sary for antiviral activity (Pitossi et al., 1993). However, 
the important question of whether GTPase activity is re- 
quired or whether GTP-binding per se is of critical impor- 
tance could so far not be answered. Mutational analysis 
further indicated that sequences near the C-terminus of 
MxA determine its antiviral specificity~ a mutant of MxA 
with a single glutamine to arginine substitution at posi- 
tion 645 was inactive against VSV when expressed in 
mouse 3T3 cells, but remained active against influenza 
A virus (ZQrcher et al., 1992b) and Thogoto virus (Hailer 
et aL, 1993). 
MxA inhibits different steps of the multipl ication cycles 
of VSV, influenza A virus, and measles virus. MxA inhibits 
primary transcription of the VSV genome by the parental 
viral transcriptase in transfected mouse 3T3 and U937 
cells (Schnorr eta/., 1993; Staeheli and Pavlovic, 1991). 
In contrast, the MxA-sensit ive step of the influenza A 
virus multipl ication cycle is not primary transcription 
which takes place in the nucleus of the infected cells. 
Rather, the target of MxA action is a poorly defined later 
step that fol lows primary transcription but precedes viral 
genome amplif ication (Pavlovic et al., 1992). When artifi- 
cial ly moved to the nucleus with a foreign nuclear trans- 
port signal, MxA gains the ability to interfere with primary 
transcription of influenza virus (ZQrcher et aL, 1992b). 
This result is believed to indicate that MxA can interact 
with an influenza viral component that is present in the 
nucleus and the cytoplasm (Pavlovic eta/., 1992; Staeheli 
eta/., 1993). In the case of measles virus, MxA seems 
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to have a selective inhibitory effect on viral glycoprotein 
synthesis without significantly affecting viral transcription 
and replication (Schnorr et aL, 1993). 
In vitro mRNA synthesis by purified VSV ribonucleo- 
protein complexes (RNPs) is a well characterized pro- 
cess. Active VSV RNI~s can be prepared from detergent- 
disrupted virions and from virus-infected cells (Peluso 
and Meyer, 1983; Szilagyi and Uryvayev, 1973). They con- 
sist of the genomic negative-strand viral RNA, the viral 
nucleocapsid protein N and the viral polymerase sub- 
units L and P (Emerson, 1976). In the presence of the 
four ribonucleoside triphosphates and magnesium ions, 
purified VSV RNPs synthesize mRNAs with functional 
caps and poly(A) tails. Transcription initiates at the 3' 
end of the viral genome, yielding an uncapped leader 
RNA of 47 nucleotides (Banerjee and Barik, 1992; Ban- 
erjee and Chattopadhyay, 1990). The polymerase then 
reinitiates at the nearby N gene promoter to produce 
capped and polyadenylated N mRNA (Banerjee and 
Barik, 1992). As it moves along the linear viral genome, 
the VSV polymerase reinitiates at the internal promoters 
of the downstream genes and produces the correspond- 
ing capped and polyadenylated transcripts. Since some 
polymerase complexes fall off the template at the in- 
tergenic junctions before reinitiating, the genes located 
near the 3' end of the genome are expressed at higher 
rates than those located further downstream (Banerjee 
and Barik, 1992). 
Although previous in vivo experiments have clearly 
shown that the presence of MxA prevents accumulation 
of primary viral transcripts in infected cells (Staeheli and 
Pavlovic, 1991), it was still possible that the observed 
inhibition was an indirect effect of MxA action. Further, 
it was unclear whether MxA acted alone or in concert 
with other host cell factors. In this report we demonstrate 
that purified MxA could inhibit the transcriptional activity 
of RNPs purified from VSV particles, suggesting that host 
cell factors played no major role. Although MxA prepara- 
tions with high specific GTPase activity were required to 
inhibit VSV transcription in vitro, this biochemical activity 
was apparently not of functional importance for antiviral 
activity because inhibition was observed in the presence 
of GTP analogs that cannot be hydrolyzed by MxA. 
MATERIALS AND METHODS 
Plasmids 
The plasmid pHis-MxA (Pitossi etaL, 1993)is a pQE9- 
derived construct that permits high-level expression of a 
histidine-tagged variant of human MxA protein in E. coil. 
It was shown that the extra histidine residues which are 
located at the N-terminus do not interfere with the antivi- 
ral activity of MxA in rive (J. Pavlovic, personal communi- 
cation). A cDNA that codes for the mutant protein MxA- 
E645R (ZOrcher et a/., 1992b) was subcloned into the 
vector pQE9 as follows= plasmid pHMGMxA(R645) 
(ZOrcher et aL, 1992b) was cut with Clal and Smal to 
release a 2-kb fragment that contained the complete 
open reading frame for this mutant MxA protein, except 
for its initiation codon. This DNA fragment was isolated, 
blunted with Klenow polymerase, and ligated in the cor- 
rect orientation into the blunted BamHI site of vector 
pQE9. The resulting plasmid codes for His-MxA-E645R, 
a histidine-tagged protein that differs from the histidine- 
tagged wild-type MxA by having an arginine residue at 
position 645 instead of glutamine. Furthermore, in wild- 
type His-MxA the sequence Met-Val links the histidine 
tag to the MxA sequence, whereas in His-MxA-E645R 
a single Asp residue serves as a linker. 
Plasmid pHis-MxA-ASal codes for a GTPase-inac- 
tive mutant MxA protein with a C-terminal truncation of 
300 amino acids, designated His-MxA-Z&Sal. Itwas cre- 
ated by cutting plasmid pHis-MxA (Pitossi et aL, 1993) 
with Sail and Hindlll, followed by Klenow polymerase 
treatment and religation. 
Purification of histidine-tagged MxA proteins from E. 
coli 
Histidine-tagged wild-type and mutant MxA proteins 
were purified by affinity chromatography on Ni-chelate 
agarose columns, followed by MonoQ FPLC. Six to 12 
liters of E. col/culture were worked up in a typical experi- 
ment. The Ni-chelate agarose chromatography was done 
as described (Pitossi et aL, 1993) with slight modifica- 
tions. Briefly, the pQE-based expression plasmids were 
introduced into E. coil strain M15, and expression of the 
desired histidine-tagged MxA proteins was induced by 
adding 0.03 mM IPTG to the medium after the culture 
had reached an OD60o of 0.3. After 2 hr at 28 ° , the cells 
were harvested by centrifugation and resuspended in 10 
ml-of ice-cold buffer A (50 mM Tris-HCI, pH 8.0, 500 
mM NaOl, 5 mM MgCI2, 10 mM 2-mercaptoethanol, 10% 
glycerol, 0.1% N P40, 2 mM imidazole and protease inhibi- 
tors) per liter of E. coil culture. After seven cycles of 
sonication for 30 sec on ice with a Branson 250 sonifier, 
the soluble proteins were separated from the cell debris 
by centrifugation for 30 min at 20,000 X g. All subsequent 
steps were performed at 4 °. The supernatant was passed 
three times through a Ni-chelate agarose column (0.5 to 
0.8 ml bed volume per liter of E. coil culture) that was 
equilibrated with buffer A. Alternatively, 40 ml of cell-free 
supernatant was gently mixed with 2 ml of packed Ni- 
chelate agarose in a 50-ml Falcon tube with an overhead 
shaker for 2 h, before the material was poured into a 
chromatography column. The column was washed with 
20 bed volumes of buffer A containing 20 mM imidazole 
and subsequently with 20 bed volumes of buffer B (20 
mM Tris-HCI, pH 8.0, 100 mM KCI, 5 mM MgOl2, 10 
mM 2-mercaptoethanol, 20% glycerol, 0.1% NP40, 20 mM 
imidazole and protease inhibitors). Bound proteins were 
finally eluted from the column with buffer B containing 
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250 mM imidazole. Wild-type and mutant H is -MxA pro- 
teins purified in this manner were typically about 90% 
pure. 
To further purify these MxA preparations, the materials 
eluted from the Ni-chelate agarose columns were directly 
applied to a MonOQ FPLC chromatography column (Phar- 
macia, Freiburg, Germany) equilibrated with buffer C (20 
mM Tris-HCI, pH 8.0, 100 mM KCI, 10% glycerol, 1 mM 
DTi-, 0.1% NP40). Proteins retained under these conditions 
were eluted with a linear gradient of 100 to 1000 mM KCI 
in buffer C at a flow rate of 0.5 ml per rain. H is -MxA and 
His-MxA-E645R eluted at about 400 mM KCI, whereas 
His-MxA-Z&Sal eluted at about 300 mM KCI. The MxA 
protein fractions with the highest protein concentrations 
were applied to NAP-5 desalting columns (Pharmacia, 
Freiburg, Germany) equilibrated with buffer D (50 mM 
Tris-HCI, pH 8.0, 100 mM NaCI, 5 mM MgCI, 2 mM Dq-I-) 
containing 10% glycerol and 0.1% NP40, and the eluted 
material was used immediately or stored at -80  °. MxA 
proteins purified in this manner were typically more than 
95% pure. Peak fractions contained about 2 to 3 mg of 
protein per ml. Specific GTPase activity was usually not 
more than twofold reduced after 2 weeks of storage. To 
circumvent he desalting step which typically resulted in a 
significant drop of GTPase activity, the Ni-chelate agarose 
column eluates were applied to MonoQ FPLC columns 
equilibrated with buffer D containing 10% glycerol and 
0.1% NP40, and proteins were eluted with a linear gradient 
of 100 to 1000 mM NaCI (rather than KCI) which has no 
inhibitory effect on VSV in vitro transcription. MxA proteins 
eluted at about 300 mM NaCI; protein concentrations in 
the peak fractions were up to 15 mg/ml. 
Assay for determining GTPase activity of MxA 
proteins 
GTPase assays were performed at 37 ° in buffer E (50 
mM Tris-HCI, pH 8.0, 5 mM MgCI2, 0.1 mM Dqq-, 130 
nM adenosine-5'[/g-T-imido]triphosphate, 10% glycerol) 
that contained 1 mM unlabeled GTP and 13 nM [~32p]_ 
GTP (3000 Ci/mmol, Amersham, Braunschweig, Ger- 
many). MxA proteins were used at a final concentration 
of about 0.1 mg/ml. The reactions were stopped at vari- 
ous times by adding an equal volume of a solution con- 
taining 2 mM EDTA and 0.5% SDS. Samples were spotted 
on polyethylenimine-cellulose (PEI) thin-layer chroma- 
tography plates (MN300, Machery-Nagel, D0ren, Ger- 
many) and resolved in buffer F (1 M acetic acid, 1 M LiCI). 
The signals were quantified with a digital autoradiograph 
LB286 (Berthold, Wildbad, Germany). The specific 
GTPase activity of each MxA preparation was calculated 
from several time points that were within the linear range 
of the hydrolysis reaction. 
Purification of VSV RNPs from infected cells and from 
purified virus 
VSV RNPs from infected cells were prepared by stan- 
dard procedures (Peluso and Meyer, 1983). Briefly, sub- 
confluent monolayers of BHK-21 cells (typically eight 150- 
mm dishes) were infected with 10 PFU per cell of VSV 
serotype Indiana and incubated for 6 hr at 37 °. Cells were 
then washed with PBS and incubated for 1 min on ice 
with 4 ml per dish of lysolecithine (250 #g/ml in water), 
and the lysolecithine solution was thoroughly removed. 
The dishes were left in the cold for 20 more min, 200 #1 
of buffer D was added to each dish, and the cells were 
scraped off with a rubber policeman, collected into Ep- 
pendorf tubes, and centrifuged at 8000 x g for 5 min. 
Samples of supernatants (400 #1) were loaded onto glyc- 
erol step gradients (top, 250 #1 of 30% glycerol in buffer 
D; bottom= 50 #1 of 100% glycerol). After centrifugation at 
200,000 X g for 2 h the viral RNPs formed a visible band 
between the 100 and the 30% glycerol layers. RNPs were 
collected and stored at -80  °. 
Preparation of VSV RNPs from purified virus particles 
was as follows, a high titer stock of VSV serotype Indiana 
was produced in BHK-21 cells, and the virus was purified 
as described (De and Banerjee, 1984). Purified virus (240 
fig of protein in 480 #1 of 20 mM Tris-HCI, pH 7.5, 1 mM 
EDTA, 100 mM NaCI) was disrupted by adding 120 #1 of 
buffer G (50 mM Tris-HCI, pH 8.0, 25% glycerol, 1.6 M 
NaCI, 9.25% Triton X-100, 3 mM Dqq-) for 10 min on ice, 
and centrifuged in a Beckman SW60 rotor at 300,000 g 
for 2 hr through 30% glycerol in buffer D onto a 
100% glycerol cushion. RNPs were collected and stored 
at -80  ° . 
Calculations of the VSV RNP to MxA ratio 
The number of VSV RNPs in the VSV in vitro transcrip- 
tion reactions were estimated by determining the con- 
centration of VSV P protein on immunoblots and assum- 
ing that each RNP contains some 400 molecules of P 
protein (Thomas eta/., 1985). Recombinant VSV P protein 
served as a standard. It was expressed in E. coil and 
purified as described (Barik, 1992). Serial dilutions of 
purified P protein standard and samples of the VSV RNP 
preparations were applied to SDS-PAGE and the pro- 
teins were blotted on nitrocellulose membranes and de- 
veloped with rabbit antibodies to gel-purified recombi- 
nant VSV P protein. The immunoblots revealed that about 
0.037 ffg/#l of P protein were present in the VSV RNP 
preparation that we obtained from infected cells and that 
some 5 #g/ffl of P protein were present in the VSV RNPs 
that we obtained from purified virus. Taken into account 
that approximately 400 molecules of P protein are pres- 
ent in one RNP complex (Thomas eta/., 1985), the VSV 
RNP concentration was calculated to be 1.4 X 109/#1 for 
the RNPs from infected cells and 2.6 × 101~/#1 for the 
RNPs from purified virus. A typical VSV in vitro transcrip- 
tion assay of 20 #1 total volume contained 0.7 #1 of VSV 
RNPs from infected cells or 0.1 ffl of VSV RNPs from 
purified virus. Since we typically used 1 #g/#l of MxA 
that corresponds to some 1.6 X 10 ~4 MxA molecules per 
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20 #1 of assay mixture, the RNP to MxA ratio was 1 to 
1.1 × 105 and 1 to 6 X 103 for VSV RNPs from infected 
cells and purified virus, respectively. 
VSV in vitro transcrip.tion assay 
Transcription assays were carried out as described 
(Barik and Banerjee, 1991). The reactions were done in 
20 #1 of buffer D that contained 1 mM each of GTP, ATP, 
and UTP, 50 #M unlabeled OTP, 33 nM [~-32P]OTP (3000 
mOi/mmol, Amersham, Braunschweig, Germany), 1.5 U/ 
#1 of RNase inhibitor (Pharmacia, Freiburg, Germany), 
and various amounts of MxA proteins. Changes in salt 
concentrations caused by the addition of MxA were kept 
to a minimum, and if not avoidable they were adjusted 
in the control reactions. Reactions typically contained 
about 0.1 to 1 #1 of VSV RNPs. Where indicated, the 
reaction mixture was supplemented with 0.25 #g/#l of 
tRNA. This additive was found to effectively titrate out 
traces of RNase activity present in some preparations of 
wild-type and mutant His-MxA. In some experiments, 
GTP was replaced by an equal amount of either guano- 
sine-5'[p-3/-imido]triphosphate (GMP-PNP) or guano- 
sine-5'[~-~,-thio]triphosphate (GTP3~S; Boehringer-Mann- 
helm, Mannheim, Germany), which serve as substrates 
for the VSV transcriptase (Eckstein, 1985) but cannot be 
hydrolyzed by MxA proteins. The samples were incu- 
bated for 100 min at 30 ° before 2 #1 of a 1 mM solution 
of CTP was added. After incubation at 30 ° for another 10 
min, 100 ng of oligo(dT)18 and 0.5 U of RNase H (Amer- 
sham, Braunschweig, Germany) were added and the mix- 
ture was incubated for 10 min at 30 ° to degrade poly(A) 
tails from the VSV transcripts. Reactions were stopped 
by adding 0.5% SDS and 50 fig of carrier tRNA. The 
samples were extracted with phenol and chloroform, and 
the RNAs were precipitated with ethanol. RNA pellets 
were dissolved in 5 #1 of 95% formamide and resolved 
by running through a 6% polyacrylamide-urea gel. The 
dried gel was exposed to X-ray films or quantified with 
a phosphoimager (Molecular Dynamics). 
Measurements of nucleotide pools and analysis of 
GTP hydrolysis products by HPLC 
HPLC analysis was carried out as described (Tucker 
et aL, 1986) with slight modifications. Briefly, a C18 re- 
versed-phase column (0.4 X 25 cm filled with ODS Hyper- 
sil, 5 fire; Bischoff, Leonberg, Germany) was run at ambi- 
ent temperature at a flow rate of 1 ml/min in 50 mM 
Na-phosphate (pH 6.5) containing 0.2 mM tertiary buty- 
lammoniumbromide, 3% of acetonitrile, and 0.2 mM 
NAN3. In this system, GDP elutes at 6.8 min, GTP at 9.5 
min, ADP at 14 min, and ATP at 22 min. The concentration 
of the nucleotides in the VSV transcription reaction mix- 
tures were determined by applying 3-#1 samples to the 
column, measuring the absorption at 252 nm with a 
VWM-2141 uv detector (Pharmacia, Freiburg, Germany), 
and quantitating the signals with a C-R5A integrator (Shi- 
madzu, Kyoto, Japan). 
RESULTS 
Purification of GTPase-active histidine-tagged MxA 
protein 
We previously reported (Pitossi et aL, 1993) that 
GTPase-active MxA protein with a histidine tag at the N- 
terminus (His-MxA) can be purified from E. coil by a 
single round of affinity chromatography on Ni-chelate 
agarose. An example of such a purification is shown in 
Fig. 1A. Strain M15 of E. coil carrying an appropriate 
pQE expression construct could be induced with IPTG 
to produce large amounts of His-MxA (Fig. 1A, lanes 1 
and 2). The bulk of His-MxA was present in soluble form 
after lysis of the bacteria by sonication (Fig. 1A, lane 3) 
and bound to Ni-chelate agarose. After washing, bound 
His-MxA was eluted from the column with a buffer that 
contained 250 mM imidazole (Fig. 1A, lanes 9-12). His- 
MxA in the peak fraction was about 90% pure. To purify 
MxAto near homogeneity, the Ni-chelate column eluates 
were applied to a MonoQ FPLC column, and bound His- 
MxA was eluted with a linear gradient of KCI (Fig. 1B). 
His-MxA in the peak eluate fractions was at least 95% 
pure, as judged from PAGE gels stained with Coomassie 
blue. Our initial attempts to inhibit in vitro transcription 
of VSV with such preparations of His-MxA showed that 
KCI and other buffer components were inhibitory. To 
eliminate this problem, purified His-MxA was run over 
NAP-5 desalting columns that were equilibrated with VSV 
transcription buffer. In other experiments we used a mod- 
ified MonoQ FPLC buffer system and eluted His-MxA 
with a linear gradient of NaCI (see Materials and Meth- 
ods). Both procedures yielded His-MxA preparations 
with specific GTPase activities varying from 15 to 300 
nmol of GTP per min per mg of MxA (Table 1). Storage 
of MxA preparations at -80 ° was possible in buffers 
containing at least 5% glycerol, but activity was gradually 
lost under these conditions. His-MxA preparations were 
therefore routinely checked for GTPase activity immedi- 
ately before use in VSV transcription assays. Wild-type 
MxA and the two mutant proteins His -MxA-ASal  and 
His-MxA-E645R showed similar behaviors during col- 
umn chromatography. Preparations of His-MxA-z&Sal 
showed no detectable GTPase activity, whereas the spe- 
cific GTPase activity of His-MxA-E645R was not signifi- 
cantly different from wild-type His-MxA (Table 1). 
MxA inhibits in vitro transcription of RNPs from VSV- 
infected cells 
Purified viral RNPs isolated from BHK-21 cells infected 
with VSV synthesize RNA when incubated at 30 ° in the 
presence of ribonucleoside triphosphates (Banerjee and 
Barik, 1992). RNA products accumulated linearly for at 
A 
kDa 
180-- 
116-- 
84--  
58-- 
48--  
36--  
26--  
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RG, 1. Purification of histidine-tagged MxA protein from E. coil Protein samples from various stages of the purification procedure were analyzed 
by SDS-PAGE and Coomassie blue staining. (A) Samples of E. coil strain M15 transfected with plasmid pQEg-MxA were lysed with L~mmli gel 
sample buffer before (lane 1) and after (lane 2) induction with 0.03 mM iPTG for 2 hr. The induced culture was lysed by sonication, and the cell- 
free lysate (lane 3) was loaded onto a Ni-chelate agarose column. The flow-through material (lane 4) was discarded. Samples of the wash buffer 
were analyzed at the beginning (lane 5) and the end (lane 6) of washing step 1 and at the beginning (lane 7) and the end (lane 8) of washing step 
2. The bound proteins were eluted in four fractions with a buffer containing 250 mM imidazole (lanes 9-12). (B) Affinity-purified His-MxA was 
Poaded onto a MonoQ FPLC column (lane 1). The materia) in the flow-through (lane 2) was discarded. The bound proteins were eluted with a linear 
gradient of KCI, and fractions from the peak region (lanes 3-12) were collected, M, molecular size marker. 
least 100 rain (Fig. 2, lanes 1 to 3). From their  gel migra-  
tion propert ies  these RNAs were  ident i f ied as the mRNAs  
coding for the viral prote ins  G, N, M, and P. A s t rongly  
reduced amount  of RNA products  was  detected  when 
highly pur i f ied H is -MxA was  added to the in vitro tran- 
scription react ion ( lane 4), No such reduct ion was  ob- 
served when a s imi la r  amount  of the C- termina l ly  trun- 
cated GTPase- inact ive  mutant  H is -MxA-z&Sa l  was  
added (lane 5). Inhibi t ion was  dependent  on the amount  
of H is -MxA that was  added= the inhib i tory effect was  
strongest ( less than 20% RNA t ranscr ipts  fo rmed com-  
pared to the control  react ion)  at a concent rat ion  of H is -  
MxA of 1 #g/#l  ( lane 4). The inhibi t ion was  still s ign i f icant  
when H is -MxA was  used at a concentrat ion  of 0.5 f ig /  
#1, whereas  the inh ib i tory  effect was  min imal  at 0.25 #g/  
#1 ( lanes 7 and 8). The VSV RNP to MxA ratio in these 
assays  (see Mater ia ls  and Methods)  was  on the order  
of 1 to 1,1 x 105. Var ious preparat ions  of w i ld - type  H is -  
MxA di f fered s ign i f icant ly  in their  inh ib i tory act iv i t ies (Ta- 
ble 1). We not iced a d i rect  corre lat ion between GTPase 
activity of a g iven MxA preparat ion  and its potent ia l  abi l i ty 
to inhib i t  VSV t ranscr ipt ion  in vitro. Furthermore,  prepara-  
t ions of act ive H is -MxA that  were  stored at -80  ° gradu-  
al ly lost both the i r  anti-VSV activity and their  GTPase 
activity. From these observat ions  it seemed that speci f ic  
GTPase activity was  a re l iab le  parameter  for  qual i ty  con- 
TABLE 1 
SPECIFIC GTPase AND ANTI-VSV ACTW~TJ~S OF VARIOUS His-MxA PREPARATIONS 
GTPase activity Inhibition of VSV 
Mx protein Preparation no. (ned GTP/min/mg Mx) in vitro transcription a 
HJs-MxA 26 300 + 
66 (fresh) b 152 + 
229 95 + 
48 (fresh) ~ 68 + 
55 15 - 
66 (old) b <20 - 
48 (old) b <20 - 
His-MxA-E645R 13 150 - 
235 95 - 
65 34 - 
His-MxA-z~Sal 47 Not detected - 
54 Not detected - 
a+ Indicates that this preparation of His-MxA reduced RNA product levels by more than fourfold when used at final concentrations of about 1 
#g/#l. - -  Indicates that no significant reductions of RNA product levels were detected under these conditions. 
bThe His-MxA preparations 66 and 48 exhibited GTPase activity and inhibited VSV in vitro transcription in experiments performed after these 
proteins were freshly purified (fresh). Upon storage at -80 ° for longer than 5 weeks (old), these preparations lost GTPase and antiviral activities. 
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1 2 3 4 5 6 7 8 
G~ 
H- -  
1 2 3 4 5 
G~_.  
tirne(min) 25 50 100 100 100 100 100 100 
His-MxA (#g/~tl) 1 0.5 0.25 
His-MxA-ASal (l~g/#l) . . . .  1 
FIG. 2. Inhibition of VSV in vitro transcription by purified His-MxA. 
RNPs isolated from VSV-infected cells were allowed to transcribe in 
vitro under standard conditions for the indicated times in the presence 
of various amounts of purified His-MxA (prep. 66) or the C-terminally 
truncated variant His-MxA-ASal (prep. 54). The radiolabeled tran- 
scription products were separated on 6% polyacrylamide-urea geis 
and visualized by autoradiography. The expected gel positions of tran- 
scripts derived from the VSV N, P, M, and G genes are marked. 
trol= H is -MxA preparations with specific GTPase activi- 
ties lower than approximately 50 nmol GTP/min/mg MxA 
showed little or no inhibitory activity in the VSV in vitro 
transcription system at 1 f fg/ f f l  (Table 1). 
To dist inguish between the possibil it ies that the inhibi- 
tory effect of MxA was due to interference with the tran- 
scription process or that MxA had a destabil izing effect 
on viral mRNAs, we incubated H is -MxA with preformed 
radiolabeled VSV transcripts and checked for degrada- 
tion by gel electrophoresis (Fig. 3). In one set of reactions 
H is -MxA and mutant H is -MxA-ASa l  were added at 
time zero and the reactions were incubated for 100 min 
at 30 ° (lanes 2 and 3). In a second parallel set of reactions 
the MxA preparations were added after 100 min of unim- 
paired transcription at 30 °. By this time radiolabeled viral 
mRNAs had accumulated (lane 1). Preformed mRNAs 
were incubated for another 60 min at 30 ° in the absence 
(lane 4) or presence of MxA preparations (lanes 5 and 
6), and analyzed by gel electrophoresis. Wild-type H is -  
MxA efficiently inhibited the accumulation of viral RNAs 
when continuously present in the reaction (lane 2), but 
had no signif icant effect when added to preformed viral 
1 2 3 
/ l  
=, ,P ,~ 
4 5 6 
4 
Mx acided 
after 100 min 
Mx added 
at lime zero 
FiG. 3. Stability of VSV transcripts is not affected by MxA. RNPs 
isolated from VSV-infected cells were allowed to transcribe in vitro 
under standard conditions. His-MxA (prep. 48) orthe C-terminally trun- 
cated variant His-MxA-ASal (prep. 47) (final concentrations of 1.2/~g/ 
#1) were added to the transcription reaction at time zero (lanes 1-3) 
or at 100 min (lanes 4-6). Reactions were stopped after 100 min (lanes 
1-3) or after 160 min (lanes 4-6). 
time(rnin) 25 50 100 100 100 
His-MxA (~tg]~l) 0.5 
His-MxA-ASal (pg/~l) - 0.5 
FIG. 4. Purified His-MxA inhibits in vitro transcription catalyzed by
RNPs prepared from mature VSV particles. Transcription conditions 
and analysis of the RNA products were as in Fig. 2, except that the 
RNPs were isolated from a highly purified stock of VSV. Reactions were 
performed in the presence or absence of 0.5 #g/ffl of His-MxA (prep. 
66) or the C-terminally truncated variant His-MxA-ASal (prep. 54). 
The fuzzy appearance of the RNA bands in lane 4 was probably caused 
by traces of contaminating RNases present in this preparation of MxA. 
RNase activity was occasionally observed in both wild4ype and mutant 
MxA preparations; its effects on VSV in vitro transcripts could be titrated 
out by performing the reactions in the presence of 0,25 #g//~l of tRNA 
(see text and Figs..5 and 6). 
RNAs (lane 5). As expected, the mutant protein H is -  
MxA-ASa l  (lanes 3 and 6)was ineffective in both experi- 
mental settings. We thus concluded that VSV mRNA sta- 
bility was not affected by MxA. Rather, inhibition ap- 
peared to result from interference of MxA with the tran- 
scription process itself. 
We tested the remote possibi l ity that H is -MxA,  which 
forms high-molecular-weight ol igomers (M. Schwemmle 
and M. F. Richter, unpubl ished results) like other purified 
Mx proteins (Melen et aL, 1992; Nakayama et aL, 1993), 
caused inhibition of transcription by precipitating the VSV 
RNPs. However, this seemed not to be the case. When 
the reaction tubes were spun at 30,000 g for 15 min 
after VSV transcription was performed in the presence 
or absence of H is -MxA,  we found similar amounts of 
VSY P protein in the pellet fractions (data not shown). 
Host cell factors seem not to play a major role for 
the MxA-mediated inhibition of transcription 
From the experiments described above it remained 
unclear whether MxA acted alone or together with un- 
known cel lular factors present in our crude RNP prepara- 
tions. We therefore tested whether MxA could inhibit in 
vitro transcription by RNPs prepared from purified virions 
which contain only low amounts of contaminating host 
cell proteins. Such RNP preparations possessed tran- 
scription activity= the RNA products had the same sizes 
as those synthesized by RNPs from infected cells (Fig. 
4, lanes 1-3). Adding wild-type H is -MxA to this reaction 
resulted in strongly reduced levels of RNA products (lane 
4), whereas the GTPase-inactive mutant H is -MxA-ASa l  
showed no such activity (lane 5). These f indings sug- 
gested that MxA can function without accessory proteins. 
The VSV RNP to MxA ratio in these assays (see Materials 
and Methods) was on the order of 1 to 6 X 10 3. A closer 
inspection of the autoradiogram shown in Fig. 4 revealed 
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leader RNA-- 
RG. 5. In vitro VSV leader RNA synthesis is inhibited by His-MxA. 
Samples of in vitro transcription reactions performed in the absence 
or in the presence of 1 #g/#l of His-MxA (prep. 229) were loaded 
on a 6% polyacrylamide-urea gel. The run was stopped when the 
bremphenol dye had migrated about 12 cm. An unrelated radiolabeled 
46rot RNA oligonucleotide served to identify the position of the 47-nt 
VSV leader RNA. 
that the viral RNAs synthesized in the presence of His-  
MxA migrated faster in the gel than the control RNAs. 
This effect is likely to be a gel artifact, because viral 
RNAs synthesized in the presence of H is -MxA migrated 
at similar speed or slower than control RNAs in other 
experiments (for example in Fig. 3). The faint RNA signals 
of the inhibited reaction (Fig. 4, lane 4) showed a fuzzy 
appearance. This phenomenon, which was probably 
caused by traces of a contaminating bacterial RNase, 
was observed with some but not all preparations of wild- 
type and mutant His-MxA. This RNase activity could be 
titrated out by adding tRNA to the reaction mixtures (Figs. 
5-7)= all subsequent transcription experiments were 
therefore performed in the presence of 0.25 f fg/#l  tRNA. 
It seemed that the contaminating RNase had a less pro- 
nounced effect on radiolabeled VSV transcripts synthe- 
sized by RNPs from VSV-infected cells than by RNPs 
from purified virus (compare Figs. 2 and 4). Since the 
former RNP preparations were less pure, they presum- 
ably contained significant amounts of cellular RNAs 
which might titrate out the RNase activity. 
To distinguish between MxA effects on transcription initia- 
tion and RNA chain elongation, we determined whether the 
47-nucleotide VSV leader RNA was synthesized at a reduced 
rate in the presence of MxA. If MxA inhibits the elongation 
process, the effect on leader RNA synthesis should be mini- 
mal. In contrast, if MxA inhibits the initiation process, leader 
RNA synthesis should be strongly reduced. Figure 5 shows 
that an RNA product of about 47 nucleotides was present 
in the unimpaired transcription reaction, whereas this RNA 
was barely detectable in the reaction performed in the pres- 
ence of His-MxA. This result indicated that VSV leader RNA 
synthesis was restricted, suggesting that the transcription 
initiation process is the target of MxA action. 
Transcription inhibition by MxA is not due to GTP 
depletion 
A possible explanation of our results was that the MxA- 
associated GTPase activity rapidly degrades GTP in the 
reaction mixture and thus depletes the viral transcriptase 
of this nucleotide. To test this possibility, we monitored 
GTP degradation by HPLC analysis. The GTP concentra- 
tion decreased rapidly in reactions containing active 
His-MxA. Itdropped from 1 mM to 70 #M during the 
first 25. min of incubation. However, the concentrations 
of available GTP did not fall below 40 #M (data not 
shown), a value found to be sufficient for unimpaired 
transcription. Control experiments showed that the GDP 
formed during GTP hydrolysis had no inhibitory effect on 
the VSV transcription reaction (data not shown). HPLC 
analysis further demonstrated that MxA did not deplete 
the transcription reactions for ATP= more than 600 #M 
ATP was still present after incubating transcription reac- 
tions for 100 rain with 1 ffg/#l of active His-MxA. 
To confirm this result and to further evaluate the role 
of the MxA-associated GTPase activity, the in vitro tran- 
scription reactions were carried out in the presence of 
GMP-PNP or GTP1/S. These GTP analogs have a non- 
cleavable bond between the ~ and the I/ phosphates 
and cannot be hydrolyzed by MxA (data not shown), but 
they serve as substrates for the VSV polymerase which 
cleaves nucleoside triphosphates between the ~ and the 
/5' phosphates (Eckstein, 1985). One set of transcription 
reactions was performed in the presence or absence 
of H is -MxA under standard conditions in a buffer that 
contained 1 mM GTP. The Other set of reactions was 
performed in a buffer that contained 1 mM of either GMP- 
PNP or GTPI/S instead of GTP. Since purified H is -MxA 
has an empty nucleotide binding pocket (M. F. Richter, 
unpublished results), the transcription reactions con- 
tained no other guanine nucleotides. The rates of unim- 
paired transcription in the presence of the different nucle- 
otides were comparable (Fig. 6). More importantly, His-  
MxA inhibited the VSV transcription reaction indepen- 
dently of whether GTP, GMP-PNP, or GTP1/S were pres- 
ent as single sources of guanine nucleotides (Fig. 6), 
providing firm proof that GTP depletion played no critical 
role in the experiments described above. Furthermore, 
these results showed that although MxA preparations 
with high specific GTPase activity were required to inhibit 
VSV transcription in vitro, this hydrolysis activity was dis- 
pensable. High specific GTPase activity of MxA prepara- 
tions thus probably indicated the presence of a high 
proportion of correctly folded MxA molecules. 
No effect of mutant H is -MxA-E645R on VSV in vitro 
transcription 
MxA-E645R is a variant of MxA with altered antiviral 
specificity= it fails to inhibit VSV but still inhibits influenza 
virus multiplication in 3T3 cells (Z(Jrcher et aL, 1992b). 
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FIG. 6. Inhibition of VSV in vitro transcription by H is -MxA is not 
caused by GTP depletion. RNPs from purified VSV particles were al- 
lowed to transcribe in vitro for 100 rain in the presence or absence of 
1.8 #g/#l of H is -MxA (prep. 26). Pairs of reactions were performed 
with 1 mM of either GTP, GMP-PNP, or GTP-~S. These GTP analogs 
cannot be hydrolyzed by MxA proteins but can function in place of GTP 
in VSV mRNA synthesis. 0.25 #g/ffl of tRNA was present in all reactions. 
Analysis of radiolabeled RNA products was as in Fig. 2. 
To determine whether MxA-E645R can block transcrip- 
tion of VSV in vitro, this protein was expressed in E. coil  
with a histidine tag at its N-terminus and purified by Ni- 
chelate and MonoQ chromatography. Three independent 
preparations of H is -MxA-E645R were analyzed for in- 
hibitory activity on VSV in vitro transcription. They exhib- 
ited specific GTPase activities of 34, 95, and 150 nmol 
of GTP/min/mg protein, respectively (Table 1). The Km 
values for GTP hydrolysis by His -MxA-E645R and wild- 
type H is -MxA were similar (data not shown). The accu- 
mulation of VSV transcripts could not be inhibited signifi- 
cantly with our His-  MxA-  E645R preparations. For exam- 
ple, preparation No. 235, which had a high specific 
GTPase activity, failed to inhibit the VSV in vitro transcrip- 
tion reaction significantly at 1 ffg/#l, whereas wild-type 
H is -MxA was effective under these conditions (Fig. 7). 
This preparation of H is -MxA-E645R was able to inhibit 
in vitro transcription of influenza virus (Landis et al., 
1994). Preparation No. 13 of His-MxA-E645R, which ex- 
hibited still higher GTPase activity, could not inhibit VSV 
in vitro transcription even at 1.8 #g/#l (data not shown). 
In a final experiment, we tested whether H is -MxA-  
E645R could interfere with the antiviral activity of the 
wild-type protein. Wild-type H is -MxA (at 1 #g/#l) inhib- 
ited in vitro transcription of VSV RNPs similarly well irre- 
spective of whether 1 ffg/#l of H is -MxA-E645R (prepa- 
ration No. 13) was added (data not shown). 
DISCUSSION 
between effects on VSV mRNA stability and effects on 
de novo mRNA synthesis. In this report we demonstrated 
that purified recombinant MxA can inhibit the VSV tran- 
scription reaction in vitro. MxA has no destabilizing effect 
on VSV mRNAs but prevents the accumulation of viral 
transcripts by inhibiting the activity of the VSV poly- 
merase. 
Purification of active MxA was facilitated by a histidine 
tag that we engineered to its N-terminus. This tag al- 
lowed us to establish a fast purification protocol that 
included a-Ni-chelate affinity chromatography step fol- 
lowed by MonoQ ion exchange chromatography. The 
MxA-associated GTPase activity proved to be a reliable 
and convenient marker for monitoring the purification of 
active MxA. Good preparations of purified MxA had spe- 
cific GTPase activities of 80 to 300 nmol of GTP/min/mg 
MxA, which is close to the value determined for natural 
MxA from IFN-induced human fibroblasts (Horisberger, 
1992). Our VSV in vitro transcription experiments showed 
that MxA preparations with specific GTPase activities of 
approximately 50 nmol of GTP/min/mg MxA or higher 
exhibited significant antiviral activity under the given con- 
ditions, whereas preparations with lower GTPase activity 
did not. Thus, the minimal specific GTPase activity re- 
quired for VSV inhibition was close to the values of our 
best MxA preparations. Since MxA was found to lose 
activity during laborious work-up procedures, the avail- 
ability of a quick MxA purification protocol was of critical 
importance for successful inhibition of the in vitro VSV 
transcription reaction. 
A hallmark of the MxA-mediated inhibition of VSV in 
vivo was the variable effects on different genes= most 
pronounced on the L gene, less pronounced on the G 
gene, and least pronounced on the N, P and M genes, 
which are located closer to the 3' end of the linear viral 
genome (Staeheli and Pavlovic, 1991). The VSV in vitro 
transcription system does not yield significant amounts 
of L gene transcripts (Barik and Banerjee, 1991) so that 
the in vitro effect of MxA on the accumulation of this 
.Z 
From studies of transfected cells expressing MxA it 
became clear that this protein can confer resistance to 
VSV and several other RNA viruses (Pavlovic and 
Staeheli, 1991; Pavlovic etaL, 1990; Schnorr eta/., 1993), 
suggesting that MxA is an important mediator of the IFN- 
induced antiviral state. However, elucidating the mode of 
MxA action has been difficult due to the lack of a suitable 
in vitro system. In vivo studies showed that accumulation 
of VSV primary transcripts was inhibited by MxA (Staeheli 
and Pavlovic, 1991), but it was impossible to distinguish 
+ tRNA 
FIG. 7. Mutant H is -MxA-E645R which fails to inhibit VSV in vivo 
also fails to inhibit ranscription of VSV in vitro. RNPs from purified VSV 
particles were allowed to transcribe in vitro under standard reaction 
conditions for 100 rain in the presence of 1 #g/#l of either H is -MxA 
(prep. 229) or H is -MxA-E645R (prep. 235). Reactions were performed 
in the presence of 0.25 #g/#l of tRNA. Analysis of radiolabeled RNA 
products was as in Fig. 2. 
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gene product could not be studied. Transcription of the 
other genes seemed to be influenced to similar degrees 
by MxA. However, a precise quantification was not possi- 
ble due to the fact that the yields of in vitro-transcribed 
G mRNAs were low, even in the absence of MxA. An 
important observation was that MxA had a clear inhibi- 
tory effect on the synthesis of the 47-nucleotide VSV 
leader RNA. It thus seemed that MxA interferes with the 
transcription initiation process. 
The mutant MxA-E645R showed an interesting pheno- 
type in transfected cells= it inhibited the multiplication of 
influenza virus like wild-type MxA but failed to inhibit VSV 
(Z(Jrcher et al., 1992b). The in vivo studies could not 
clearly distinguish between the possibility that MxA-  
E645R had lost its affinity for the critical VSV target and 
the possibility that its intraoellular distribution was al- 
tered so that it could no longer interact with VSV (Z0rcher 
et al., 1992b). Our in vitro results suggested that the 
former possibility is correct= preparations of MxA-E645R 
with specific GTPase activities as high as those of antivi- 
rally active wild-type MxA failed to inhibit the VSV in vitro 
transcription reaction to a significant degree. However, 
purified His -MxA-E645R could inhibit the in vitro tran- 
scription reaction catalyzed by influenza virus RNPs (Lan- 
dis eta/., 1994), indicating that this mutant MxA protein 
has the same antiviral specificity in vivo and in vitro. 
These results confirmed our earlier conclusion that resi- 
due 645 near the C-terminus of MxA is part of a domain 
required for inhibition of VSV (Z(Jrcher eta/., 1992b). 
An important result of our in vitro studies was that MxA 
effectively blocked the accumulation of viral transcripts 
synthesized by both VSV RNPs from virus-infected cells 
and VSV RNPs from purified virions. It suggested that 
MxA can function without other host cell factors. We 
cannot formally exclude the remote possibility that MxA 
activated some contaminating enzymatic activity which 
in turn rendered the RNPs transcriptionally inactive. 
RNPs from purified virus consist of viral genomic RNA 
and the three viral proteins N, P, and L. The fact that MxA 
was effective in this system indicates that it interacts with 
one or several of these viral components. It should now 
be possible to identify and characterize these interac- 
tions. 
Our experiments revealed that relatively high concen- 
trations of active MxA were required for significant inhibi- 
tion of the VSV in vitro transcription reaction, H is -MxA 
used at 1 #g/#l or higher reduced the RNA transcript 
levels at least fivefold, whereas H is -MxA used at less 
than 0.25 #g/#l was almost ineffective. Although the 
threshold MxA concentration appears very high, it may 
faithfully reflect the situation in vivo. In IFN-treated cells, 
MxA can constitute 0.5 to 1% of cytosolic proteins (Hori- 
sberger, 1992). MxA concentrations in vivo may thus be 
higher than 1 #g/#l cytosol. 
Experiments with transfected 3T3 cells indicated that 
such high intracellular concentrations of MxA are indeed 
required for good protection against VSV (Pavlovic eta/., 
1990; Z0rcher eta/., 1992b). When estimating the relative 
concentrations of in vitro transcribing VSV RNPs and in- 
terfering MxA molecules, we calculated ratios of 1 to 6 
x 103 for RNPs from virions and 1 to 1.1 x 10 ~ for RNPs 
from infected cells, indicating that a vast excess of MxA 
was required for efficient inhibition. The apparent in- 
creased efficacy of H is -MxA in the former case may 
stem in part from the fact that the specific polymerase 
activity of virion RNPs was about fivefold lower than that 
of RNPs from infected cells. It is unclear whether the 
requirement for high concentrations of MxA reflects a 
poor affinity of MxA for the viral target. It is possible that 
MxA exhibits only low intrinsic antiviral activity unless 
stimulated by an unknown activator, which was missing 
in our in vitro assay system. However, our attempts to 
detect an MxA-stimulating activity in crude cell extracts 
have to date not been successful. Another possible ex- 
planation of the need for high MxA concentrations is 
that high-molecular-weight oligomers of MxA rather than 
monomers represent the antivirally active material, as 
suggested for the mouse Mxl protein (Melen eta/., 1992; 
Nakayama eta/., 1993). In fact, our recent attempts to 
determine the size of the H is -MxA oligomers by gel 
filtration experiments showed that they were about 2000 
kDa (M. Schwemmle and M. F. Richter, unpublished re- 
suits), suggesting that about 30 H is -MxA monomers 
were present in one oligomer. Thus, the ratio of active 
MxA entity to viral RNPs may not be so much in favor of 
MxA as it appears from our calculations. 
Our in vitro experiments yielded important clues re- 
garding the role of the MxA-associated GTPase for antivi- 
ral activity. The fact that MxA exhibits GTPase activity 
(Horisberger, 1992) suggested that this activity is instru- 
mental for virus inhibition. This view was supported by 
the observation that mutations in the GTP-binding con- 
sensus motif simultaneously destroyed GTPase and anti- 
viral activity (Pitossi et a/., 1993). Furthermore, we ob- 
served in this work that GTPase activity was a reliable 
marker for MxA quality control, the capabilities of prepa- 
rations of purified wild-type MxA to inhibit the VSV in vitro 
transcription reaction correlated well with their GTPase 
activities. Nevertheless, MxA blocked VSV in vitro tran- 
scription reactions that were performed in buffers con- 
taining GMP-PNP or GTPTS in place of GTP. These GTP 
analogs have a noncleavable bond between the/3 and 
the T phosphates and can therefore not be hydrolyzed 
by MxA, but they serve as substrates for the VSV polymer- 
ase which cleaves nucleoside triphosphates between 
the G and the/3 phosphates (Eckstein, 1985). This result 
proved that MxA does not act by depleting the viral poly- 
merase of GTP. It further suggested that hydrolysis of 
GTP by MxA is not of mechanistic importance for virus 
inhibition. It thus appears that binding of GTP rather than 
hydrolysis is of critical importance. 
Our results complement work by Landis et al. (1994),. 
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who recently showed that in vitro transcription of influ- 
enza virus can be inhibited with preparations of histidine- 
tagged human MxA and mouse Mxl proteins purified by 
nickel chelate chromatography. 
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